Targeted Oncology Staff

Martin Dietrich, MD, PhD, discusses the study design and results of the CheckMate 9LA trial of ipilimumab and nivolumab for patients with non–small cell lung cancer.

During a live virtual event, Brian Rini, MD, discussed the efficacy and tolerability of approved first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced renal cell carcinoma.

During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.

During a live virtual event, Rita Nanda, MD, discussed the choice of therapy for a patient whose metastatic triple-negative breast cancer recurred after adjuvant chemotherapy with paclitaxel.

During a live virtual event, Jason Westin, MD, discussed the challenges of giving patients access to chimeric antigen receptor T-cell therapy.

During a live virtual event, Ravi Salgia, MD, PhD, discussed the use of immune checkpoint inhibitor monotherapy for a patient with non–small cell lung cancer with very high PD-L1 expression with participants.

During a live virtual event, Douglas Sborov, MD, MS, discussed the most important goals for treatment and the use of minimal residual disease assessment for a patient with transplant-eligible multiple myeloma.

During a Targeted Oncology case-based roundtable event, Hetty Carraway, MD, MBA, discussed risk factors for tumor lysis syndrome and the use of prophylactic agents.

During a Targeted Oncology case-based roundtable event, Brian Rini, MD, discussed the choice of treatment options including dual immunotherapy and tyrosine kinase inhibitors plus immunotherapy for a patient with stage IV clear cell renal cell carcinoma.

During a Targeted Oncology case-based event, Lindsey Roeker, MD, discussed risk assessment and frontline therapy for a patient diagnosed with chronic lymphocytic leukemia.

During a live virtual event, Matthew B. Rettig, MD, discussed the results of the TITAN trial of apalutamide for patients with metastatic castration-sensitive prostate cancer.

During a Targeted Oncology case-based roundtable event, Jonathan Wesley Riess, MD, MS, discussed the case of a 72-year-old patient with non–small cell lung cancer with high PD-L1 expression.

During a Targeted Oncology case-based roundtable event, Victor Yazbeck, MD, MS, discussed the data from recent clinical trials of tafasitamab/lenalidomide, polatuzumab vedotin, and loncastuximab tesirine for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Srdan Verstovsek, MD, PhD, discussed the use of JAK inhibitors for patients with higher-risk myelofibrosis.

During a Targeted Oncology case-based roundtable event, Thomas C. Krivak, MD, discussed the results of studies of PARP inhibition for patients with advanced ovarian cancer.

During a case-based roundtable event, Estelamari Rodriguez, MD, MPH, discussed the case of a patient who had lung cancer with 3 brain metastases and a RET fusion.

During a case-based roundtable event, Dan Vogl, MD, MSCE, discussed possible targeted therapies for a patient with relapsed/refractory multiple myeloma who had previously received several combination therapies.

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.

During a case-based roundtable event, Kevin Kalinsky, MD, MS, discussed clinical typing of patients with breast cancer and the results of trials of therapies for patients with HR-positive, HER2-negative breast cancer.

According to results from the phase 1b portion of the study KEYNOTE-B84 study, pepinemab plus pembrolizumab achieved complete responses in 2 of the first 3 patients with head and neck cancers enrolled.

Scott S. Tykodi, MD, PhD, and Ulka N. Vaishampayan, MBBS, discussed treatment for patients with relapsed and late-stage renal cell carcinoma based on National Comprehensive Cancer Network guidelines and recent clinical trials.

During a Targeted Oncology case-based roundtable event, Matthew A. Davids, MD, MMSc, discussed key considerations for prophylaxis and the use of rasburicase in managing tumor lysis syndrome.

During a Targeted Oncology case-based roundtable event, Srdan Verstovsek, MD, PhD, discussed the procedure of prognosis, biopsy, and treatment of a 68-year-old woman with myelofibrosis.

During a Targeted Oncology case-based roundtable event, John M. Burke, MD, discussed decision-making for third-line therapy for an elderly patient with diffuse large B-cell lymphoma.

During a live virtual event, Douglas Sborov, MD, MS, discussed the possible treatment regimens for a patient with newly diagnosed multiple myeloma who is eligible for stem cell transplant.

During a Targeted Oncology case-based roundtable discussion, Krishnansu S. Tewari, MD, discussed the use of bevacizumab, niraparib, and olaparib for patients who have completed primary chemotherapy for advanced ovarian cancer.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed the CARD trial of cabazitaxel and the VISION trial of lutetium-177 for patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmaD, discussed immunotherapy and tyrosine kinase inhibitor combinations for frontline therapy of renal cell carcinoma.

During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.